Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
The Effects of Long-Term Medication Use in Alzheimer Disease
Neurol 96:e2247-e2250, Karceski, S., 2021
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Advanced Dementia
NEJM 372:2533-2540, Mitchell, S.L., 2015
Long-Term Effects of the Concomitant Use of Memantine with Cholinesterase Inhibition in Alzheimer Disease
JNNP 80:600-607, Lopez,O.L.,et al, 2009
Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease:International Randomised Controlled
BMJ 318:633-640, 615, Rosler,M.,et al, 1999
Long-Term Tacrine (Cognex) Treatment:Effects on Nursing Home Placement and Mortality
Neurol 47:166-177, Knopman,D.,et al, 1996
30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients with Alzheimer's Disease
JAMA 271:985-991, 10231994., Knapp,M.J.,et al, 1994
Management of Neurological Disorders:Dementia
JNNP 57:1451-1456, Rossor,M.N., 1994
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014
Disease-Modifying Therapies for Alzheimers: New Drugs on the Horizon
Practical Neurology 7:16-23, Christensen,D.B., 2008
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Immunologic Treatment of Alzheimer's Disease
NEJM 341:1694-1695, Blass,J.P., 1999
Pharmacologic Treatment of Cognition in Alzheimer's Dementia
Neurol 51:S36-S44, Farlow,M.R.&Evans,R.M., 1998
An Update on Primary Drug Therapies for Alzheimer Disease
Arch Neurol 54:1406-1409, Knopman,D.S.&Morris,J.C., 1997